Sector Expert: Patrick Dolezal

LifeSci Capital



Recent Quotes

"DRRX intends to initiate a Phase 2 study of oral DUR-928 in Q4/17."

— Patrick Dolezal, LifeSci Capital (10/20/17)
more >

"DRRX has received an upfront payment of $12.5 million, and is also eligible for $5 million in the event of FDA approval for Indivior's RBP-7000."

— Patrick Dolezal, LifeSci Advisors (10/2/17)
more >

"Highlights of DRRX's second quarter include reaching a commercialization agreement with Sandoz, completing enrollment of a pivotal Phase III trial for this asset, and completing drug-drug interaction studies and a Phase Ib trial for DUR-928."

— Patrick Dolezal, LifeSci Advisors (8/9/17)
more >

"DRRX is a biopharmaceutical company with a rich development pipeline that includes an epigenetic regulator program and a portfolio of 505(b)(2) programs."

— Patrick Dolezal, LifeSci Capital (6/29/17)
more >



Due to permission requirements, not all quotes are shown.